OraSure (OSUR) 10-Q 6 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 01, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES, INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, $0.000001 par value per share
Security Exchange Name	NASDAQ
Entity File Number	001-16537
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4370966
Entity Address, Address Line One	220 East First Street
Entity Address, City or Town	Bethlehem
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18015
City Area Code	610
Local Phone Number	882-1820
Entity Common Stock, Shares Outstanding		71,960,048
Document Quarterly Report	true
Document Transition Report	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 177,676	$ 160,802
Short-term investments	29,080	48,599
Accounts receivable, net of allowance for doubtful accounts of $4,279 and $3,654	36,391	38,835
Inventories	40,350	31,863
Prepaid expenses	6,030	3,860
Other current assets	2,883	4,934
Total current assets	292,410	288,893
Noncurrent Assets:
Property, plant and equipment, net	64,943	51,860
Operating right-of-use assets, net	4,871	4,461
Finance right-of-use assets, net	1,184	1,312
Intangible assets, net	16,945	17,904
Goodwill	40,493	40,351
Long-term investments	33,706	47,718
Other noncurrent assets	1,944	1,973
Total noncurrent assets	164,086	165,579
TOTAL ASSETS	456,496	454,472
Current Liabilities:
Accounts payable	20,731	17,407
Deferred revenue	4,580	4,811
Accrued expenses and other current liabilities	17,003	22,227
Finance lease liability	522	517
Operating lease liability	1,443	1,125
Acquisition-related contingent consideration obligation	365	402
Total current liabilities	44,644	46,489
Noncurrent Liabilities:
Finance lease liability	762	895
Operating lease liability	3,557	3,591
Acquisition-related contingent consideration obligation	874	2,049
Other noncurrent liabilities	1,997	1,682
Deferred income taxes	1,118	1,195
Total noncurrent liabilities	8,308	9,412
TOTAL LIABILITIES	52,952	55,901
Commitments and contingencies (Note 11)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 71,956 and 71,738 shares issued and outstanding	0	0
Additional paid-in capital	504,949	505,123
Accumulated other comprehensive loss	(7,724)	(9,097)
Accumulated deficit	(93,681)	(97,455)
Total stockholders' equity	403,544	398,571
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 456,496	$ 454,472

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 4,279	$ 3,654
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	71,956,000	71,738,000
Common stock, shares outstanding	71,956,000	71,738,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
NET REVENUES:
Total revenue	$ 58,582	$ 31,596
COST OF PRODUCTS AND SERVICES SOLD	20,256	15,465
Gross profit	38,326	16,131
OPERATING EXPENSES:
Research and development	8,992	5,644
Sales and marketing	9,530	7,369
General and administrative	10,188	10,054
Change in the estimated fair value of acquisition-related contingent consideration	(806)	1,110
Total operating expenses	27,904	24,177
Operating income (loss)	10,422	(8,046)
OTHER INCOME (LOSS)	(119)	1,430
Income (loss) before income taxes	10,303	(6,616)
INCOME TAX EXPENSE	6,529	712
NET INCOME (LOSS)	$ 3,774	$ (7,328)
INCOME (LOSS) PER SHARE:
BASIC	$ 0.05	$ (0.12)
DILUTED	$ 0.05	$ (0.12)
SHARES USED IN COMPUTING INCOME (LOSS) PER SHARE:
BASIC	71,878	61,927
DILUTED	72,766	61,927
Products and Services [Member]
NET REVENUES:
Total revenue	$ 56,579	$ 30,886
Other Revenues [Member]
NET REVENUES:
Total revenue	$ 2,003	$ 710

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement Of Income And Comprehensive Income [Abstract]
NET INCOME (LOSS)	$ 3,774	$ (7,328)
OTHER COMPREHENSIVE INCOME (LOSS)
Currency translation adjustments	1,352	(9,221)
Unrealized gain (loss) on marketable securities	21	(442)
COMPREHENSIVE INCOME (LOSS)	$ 5,147	$ (16,991)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
OPERATING ACTIVITIES:
Net income (loss)	$ 3,774	$ (7,328)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Stock-based compensation	1,464	1,376
Depreciation and amortization	2,489	2,165
Other non-cash amortization	138	32
Provision for doubtful accounts	598	26
Unrealized foreign currency gain	(100)	(224)
Interest expense on finance leases	14	20
Deferred income taxes	(94)	(71)
Change in the estimated fair value of acquisition-related contingent consideration	(806)	1,110
Payment of acquisition-related contingent consideration	(142)	(496)
Changes in assets and liabilities
Accounts receivable	2,188	8,623
Inventories	(8,382)	248
Prepaid expenses and other assets	(766)	1,035
Accounts payable	(253)	(3,094)
Deferred revenue	(262)	780
Accrued expenses and other liabilities	(4,253)	(1,703)
Net cash (used in) provided by operating activities	(4,393)	2,499
INVESTING ACTIVITIES:
Purchases of investments		(36,945)
Proceeds from maturities and redemptions of investments	33,745	55,811
Purchases of property and equipment	(11,061)	(2,595)
Proceeds from escrow associated with business acquisitions		126
Purchase price adjustment related to business acquisition	(19)
Purchase of patent and product rights		(2,250)
Net cash provided by investing activities	22,665	14,147
FINANCING ACTIVITIES:
Cash payments for lease liabilities	(282)	(175)
Payment of acquisition-related contingent consideration	(264)	(3,004)
Proceeds from exercise of stock options	92	30
Repurchase of common stock	(1,730)	(1,408)
Net cash used in financing activities	(2,184)	(4,557)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	786	(4,439)
NET INCREASE IN CASH AND CASH EQUIVALENTS	16,874	7,650
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	160,802	75,715
CASH AND CASH EQUIVALENTS, END OF PERIOD	177,676	83,365
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes	3,671	(85)
Non-cash investing and financing activities
Accrued property and equipment purchases	4,267	1,129
Unrealized gain (loss) on marketable securities	$ 21	$ (442)

The Company

The Company	3 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
The Company	1. The overall goal of OraSure Technologies, Inc. (“OraSure” or “the Company”) is to empower the global community to improve health and wellness by providing access to accurate essential information. Our business consists of two segments: our “Diagnostics” segment, and our “Molecular Solutions” segment. Our Diagnostics business primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our Molecular Solutions business consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store biological samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbiome and animal genetics markets. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets and in the sexually transmitted infection screening market. In addition, our Molecular Solutions business provides microbiome laboratory and bioinformatics services The Diagnostics business includes tests for diseases including HIV and Hepatitis C that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our HIV product is also sold in a consumer-friendly format in the over-the-counter (“OTC”) market in the U.S. and as a self-test to individuals in a number of other countries. Our Diagnostics business includes the operations of UrSure, Inc. (“UrSure”), which was acquired and merged into OraSure in 2020. This part of the Diagnostics business develops and commercializes products that measure adherence to HIV medications including pre-exposure prophylaxis or PrEP, the daily medication to prevent HIV, and anti-retroviral medications to suppress HIV. These products include laboratory-based tests that can measure levels of the medications in a patient’s urine or blood, as well as point-of-care products currently in development. In 2020, we developed a rapid antigen self-test for COVID-19 and a COVID-19 antibody enzyme-linked immunosorbent assay (“ELISA”) for use in laboratory settings. We are seeking Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration “FDA”) for these products. Our Molecular Solutions business is operated by our subsidiaries, DNA Genotek Inc. (“DNAG”), Diversigen, Inc. (“Diversigen”), and Novosanis NV (“Novosanis”). In this business, we manufacture and sell kits that are used to collect, stabilize, transport and store a biological sample of genetic material for molecular testing. Our products are used for academic research and commercial applications, including ancestry, disease risk management, lifestyle and animal testing. In 2020, three of our collection devices were used in connection with COVID-19 molecular testing. We also sell research-use-only collection products into the microbiome market. We offer our customers a suite of genomics and microbiome services that range from package customization and study design optimization to extraction, analysis and reporting services. The microbiome laboratory and bioinformatics services are provided by Diversigen, which includes the operations of CoreBiome, Inc. (“CoreBiome”), a subsidiary we acquired in early 2019. CoreBiome and Diversigen were merged together in 2020. Novosanis manufactures and sells the Colli-Pee® collection device for the volumetric collection of first-void urine for use in research, screening and diagnostics in the liquid biopsy and sexually transmitted infection markets. Our Molecular Solutions business serves customers in many countries worldwide, including many leading research universities and hospitals.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Principles of Consolidation and Basis of Presentation The accompanying interim unaudited consolidated financial statements include the accounts of OraSure and its wholly-owned subsidiaries, DNAG, Diversigen and Novosanis. All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated. The unaudited financial statements, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. Results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results of operations expected for the full year. Summary of Significant Accounting Policies There have been no changes to the Company's significant accounting policies described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 that have had a material impact on the consolidated financial statements and related notes except as discussed herein. Investments We consider all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss. We record an allowance for credit loss for our available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. As of March 31, 2021, we determined that the decline in the market value of our available-for-sale investment was not due to credit-related factors and as such no allowance for credit-loss was necessary. The following is a summary of our available-for-sale securities as of March 31, 2021 and December 31, 2020: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value March 31, 2021 Guaranteed investment certificates $ 25,470 $ — $ — $ 25,470 Corporate bonds 37,643 48 (375 ) 37,316 Total available-for-sale securities $ 63,113 $ 48 $ (375 ) $ 62,786 December 31, 2020 Guaranteed investment certificates $ 25,132 $ — $ — $ 25,132 Corporate bonds 71,533 135 (483 ) 71,185 Total available-for-sale securities $ 96,665 $ 135 $ (483 ) $ 96,317 At March 31, 2021, maturities of our available-for-sale securities were as follows: Less than one year $ 29,334 $ 48 $ (302 ) $ 29,080 Greater than one year $ 33,779 $ — $ (73 ) $ 33,706 Fair Value of Financial Instruments As of March 31, 2021 and December 31, 2020, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature. Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). All of our available-for-sale debt securities are measured as Level 2 instruments as of March 31, 2021 and December 31, 2020. Our guaranteed investment certificates are measured as Level 1 instruments as of March 31, 2021 and December 31, 2020. Included in cash and cash equivalents at March 31, 2021 and December 31, 2020, was We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant assets Accounts Receivable. Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs. Inventories. Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating, which can be extended in certain circumstances. We continually evaluate quantities on hand and the carrying value of our inventories to determine the need for reserves for excess and obsolete inventories, based on prior experience as well as estimated forecasts of product sales. We reserve for unidentified scrap or spoilage based on historical write-off rates. We also consider items identified through specific identification procedures in assessing the adequacy of our reserve. When factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off, as in the case of lapsing expiration dates. Property, Plant and Equipment Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations. Accumulated depreciation of property, plant and equipment as of March 31, 2021 and December 31, 2020 was $55,251 and $53,604, respectively. Intangible Assets . Intangible assets consist of customer relationships, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years. Accumulated amortization of intangible assets as of March 31, 2021 and December 31, 2020 was $28,128 and $27,107, respectively. The decrease in intangibles from $17,904 as of December 31, 2020 to $16,945 as of March 31, 2021 is due to $812 in amortization expense and foreign currency translation losses of $147. Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current generally accepted accounting principles (“GAAP”) permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit . The increase in goodwill from $40,351 as of December 31, 2020 to $40,493 as of March 31, 2021 i s a result of an Foreign Currency Translation . The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than a functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income in our consolidated statements of income were $(576) and $693 for the three months ended March 31, 2021 and 2020, respectively. Accumulated Other Comprehensive Income (Loss) We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets. We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations for those subsidiaries are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at March 31, 2021 consists of $7,397 of currency translation adjustments and $327 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investment portfolio. Accumulated other comprehensive loss at December 31, 2020 consists of $8,749 of currency translation adjustments and $348 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investments portfolio. Recent Accounting Pronouncements In March 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The purpose of this update is to provide optional guidance for a limited time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this update are elective and are effective upon issuance for all entities. Management is evaluating the impact of this ASU and does not expect this update to have a material impact on the Company's Consolidated Financial Statements .

Business Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2021
Business Combinations [Abstract]
Business Combinations	3. Business Combinations UrSure On July 22, 2020, the Company acquired all of the outstanding capital stock of UrSure, Inc. (“UrSure”), pursuant to the terms of a merger agreement. The initial aggregate purchase price of this transaction was $3,000, adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into an escrow account for a limited period after closing, pursuant to indemnification obligations under the merger agreement. During the three months ended March 31, 2020, we incurred acquisition related costs of $393 including accounting, legal, and other professional fees, all of which were expensed and reported as a component of general and administrative expense in the consolidated statement of operations. No such costs were incurred for the three months ended March 31, 2021. Pursuant to our merger agreement, we may pay up to an additional $28,000 of contingent consideration over the next four years based on the achievement of certain performance criteria as defined under the agreements, including generating certain revenue dollars, and the achievement of certain clinical milestones associated with the The Company, with the assistance of an independent valuation specialist, determined the estimated acquisition-date fair value of the acquisition-related contingent consideration of $3,440. The fair value was determined using a probability-weighted model based on our assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return analysis using the probability-weighted cash flows. The fair value measurement was based on significant inputs, including the likelihood of the achievement of clinical milestones and revenue forecasts, not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The following table represents the change in contingent consideration: Balance as of December 31, 2020 $ 2,451 Payments made during the period (406 ) Change in fair value during the period (806 ) Balance as of March 31, 2021 $ 1,239 Revenues from UrSure primarily consist of grant money received to fund the development of certain new technology. Effective as of July 22, 2020, the financial results of UrSure are included in our Diagnostics segment.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventories	4. Inventories March 31, 2021 December 31, 2020 Raw materials $ 15,484 $ 15,425 Work in process 3,857 2,572 Finished goods 21,009 13,866 $ 40,350 $ 31,863 The inventory balance of $40,350 as of March 31, 2021 includes $2,722

Earnings (Loss) Per Share

Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	5. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive. The computations of basic and diluted earnings (loss) per share are as follows: Three Months Ended March 31, 2021 2020 Net income (loss) $ 3,774 $ (7,328 ) Weighted-average shares of common stock outstanding: Basic 71,878 61,927 Dilutive effect of stock options, restricted stock, and performance stock units 888 — Diluted 72,766 61,927 Earnings (loss) per share: Basic $ 0.05 $ (0.12 ) Diluted $ 0.05 $ (0.12 ) For the three months ended March 31, 2021, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 421 shares were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. For the three months ended March 31, 2020, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 312 shares were excluded from the computation of diluted loss per share .

Revenues

Revenues	3 Months Ended
	Mar. 31, 2021
Revenue From Contract With Customer [Abstract]
Revenues	6 . Revenues Revenues by product . The following table represents total net revenues by product line: Three Months Ended March 31, 2021 2020 Infectious disease testing $ 11,371 $ 14,664 Risk assessment testing 1,962 3,000 Genomics 11,064 8,393 Microbiome 2,088 1,577 COVID-19 27,389 394 Laboratory services 2,497 2,415 Other product and service revenues 208 443 Net product and services revenues 56,579 30,886 Royalty income 1,261 446 Other non-product revenues 742 264 Other revenues 2,003 710 Net revenues $ 58,582 $ 31,596 Revenues by geographic area . The following table represents total net revenues by geographic area, based on the location of the customer: Three Months Ended March 31, 2021 2020 United States $ 49,100 $ 21,616 Europe 4,552 2,805 Other regions 4,930 7,175 $ 58,582 $ 31,596 Customer and Vendor Concentrations . We had no significant customer concentrations (greater than 10%) in our accounts receivable at March 31, 2021. One of our customers accounted for 11% of our accounts receivable as of December 31, 2020. One customer accounted for 17% of net consolidated revenues for the three months ended March 31, 2021. We had no significant customer concentrations in our net consolidated revenues for the three months ended March 31, 2020. We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Third-party suppliers also manufacture certain products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations . Deferred Revenue . We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of March 31, 2021 and December 31, 2020 includes customer prepayments of $3,000 and $3,216, respectively. Deferred revenue as of March 31, 2021 and December 31, 2020 also includes $1,580 and $1,595, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that average price.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2021
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	7 . Accrued Expenses and other current liabilities March 31, 2021 December 31, 2020 Payroll and related benefits $ 8,037 $ 14,769 Professional fees 1,150 978 Accrued income taxes 2,507 — Sales tax payable 2,572 2,400 Other 2,737 4,080 $ 17,003 $ 22,227

Leases

Leases	3 Months Ended
	Mar. 31, 2021
Lessee Disclosure [Abstract]
Leases	8 . Leases We determine whether an arrangement is a lease at inception. We have operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of March 31, 2021, we are the lessee in all agreements. Our leases have remaining lease terms of 1 to 7 years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. We have lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, we account for lease components separate from non-lease components. The components of lease expense are as follows: Three Months Ended 2021 2020 Operating Lease Cost $ 420 $ 313 Finance Lease Cost Amortization of right-of use assets 127 163 Interest on lease liabilities 14 20 Total Finance Lease Cost $ 141 $ 183 Supplemental cash flow information related to leases is as follows: Three Months Ended 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 408 $ 316 Operating cash flows from financing leases 14 20 Financing cash flows from financing leases 282 175 Non-cash activity: Right-of-use assets obtained in exchange for operating lease obligations 629 — Right-of-use assets obtained in exchange for finance lease obligations — — Supplemental balance sheet information related to leases is as follows: March 31, 2021 December 31, 2020 Operating Leases Right-of-use assets $ 4,871 $ 4,461 Current lease liabilities 1,443 1,125 Non-current lease liabilities 3,557 3,591 Total operating lease liabilities $ 5,000 $ 4,716 Finance Leases Right-of-use assets $ 1,184 $ 1,312 Current lease liabilities 522 517 Non-current lease liabilities 762 895 Total finance lease liabilities $ 1,284 $ 1,412 Weighted Average Remaining Lease Term Weighted-average remaining lease term—operating leases 3.99 Weighted-average remaining lease term—finance leases 2.43 Weighted Average Discount Rate Weighted-average discount rate—operating leases 4.12 % Weighted-average discount rate—finance leases 4.39 % As of March 31, 2021, minimum lease payments by period are expected to be as follows: Finance Operating 2021 (excluding the three months ended March 31, 2021) $ 424 $ 1,236 2022 566 1,616 2023 336 901 2024 25 909 2025 5 518 Thereafter — 323 Total Minimum Lease Payments 1,356 5,503 Less: imputed interest (72 ) (503 ) Present Value of Lease Liabilities $ 1,284 $ 5,000

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Stockholders' Equity	9 . Reconciliation of the changes in stockholders' equity for the three months ended March 31, 2021 and 2020 Common Stock Additional Paid-in Accumulated Other Comprehensive Accumulated Shares Amount Capital Loss Deficit Total Balance at December 31, 2020 71,738 $ — $ 505,123 $ (9,097 ) $ (97,455 ) $ 398,571 Common stock issued upon exercise of options 11 — 92 — — 92 Vesting of restricted stock and performance stock units 318 — — — — Purchase and retirement of common shares (111 ) — (1,730 ) — — (1,730 ) Stock-based compensation — — 1,464 — — 1,464 Net income — — — — 3,774 3,774 Currency translation adjustments — — — 1,352 — 1,352 Unrealized gain on marketable securities — — — 21 — 21 Balance at March 31, 2021 71,956 $ — $ 504,949 $ (7,724 ) $ (93,681 ) $ 403,544 Common Stock Additional Paid-in Accumulated Other Comprehensive Accumulated Shares Amount Capital Loss Deficit Total Balance at December 31, 2019 61,731 $ — $ 401,814 $ (12,136 ) $ (82,533 ) $ 307,145 Common stock issued upon exercise of options 6 — 30 — — 30 Vesting of restricted stock and performance stock units 486 — — — — — Purchase and retirement of common shares (197 ) — (1,408 ) — — (1,408 ) Stock-based compensation — — 1,376 — — 1,376 Net loss — — — — (7,328 ) (7,328 ) Currency translation adjustments — — — (9,221 ) — (9,221 ) Unrealized loss on marketable securities — — — (442 ) — (442 ) Balance at March 31, 2020 62,026 $ — $ 401,812 $ (21,799 ) $ (89,861 ) $ 290,152 Stock-Based Awards We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than shares purchased on the open market. Total compensation cost related to stock options for the three months ended March 31, 2021 and 2020 was $250 Net cash proceeds from the exercise of stock options were $92 and $30 for the three months ended March 31, 2021 and 2020, respectively. As a result of our net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises during these periods. The following table summarizes the stock option activity for the three months ended March 31, 2021: Options Outstanding on January 1, 2021 1,232 Granted 252 Exercised (11 ) Forfeited (23 ) Outstanding on March 31, 2021 1,450 Compensation cost of $1,036 and $1,079 related to restricted shares was recognized during the three months ended March 31, 2021 and 2020, respectively. The following table summarizes time-vested restricted stock award and restricted stock unit activity for the three months ended March 31, 2021: Units Issued and unvested, January 1, 2021 659 Granted 275 Vested (206 ) Forfeited (5 ) Issued and unvested, March 31, 2021 723 We grant performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year three-year Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested. Compensation cost of $178 and $44 related to PSUs was recognized during the three months ended March 31, 2021 and 2020, respectively. The following table summarizes the PSU activity for the three months ended March 31, 2021: Units Issued and unvested, January 1, 2021 651 Granted 186 Performance adjustment 37 Vested (112 ) Forfeited (49 ) Issued and unvested, March 31, 2021 713 Stock Repurchase Program On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired during the three months ended March 31, 2021 and 2020.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	10 . Income Taxes During the three months ended March 31, 2021 and 2020, we recorded income tax expense of $6.5 million and $712, respectively. Tax expense reflects taxes due to the taxing authorities and the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of March 31, 2021 and December 31, 2020 relate to the tax effects of the basis difference between the intangible assets acquired in our acquisitions for financial reporting and for tax purposes along with basis differences arising from accelerated tax depreciation of fixed assets. In 2008, we established a full valuation allowance against our U.S. deferred tax asset. Management believes the full valuation allowance is still appropriate at both March 31, 2021 and December 31, 2020 since the facts and circumstances necessitating the allowance have not changed.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11 . Commitments and Contingencies From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

Business Segment Information

Business Segment Information	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Business Segment Information	12 . Business Segment Information Our business consists of segments: our “Diagnostics” business, which primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our Diagnostics segment includes the financial results of UrSure. Our “Molecular Solutions” business consists of the development, manufacture, marketing and sale of specimen collection kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets; and in the sexually transmitted infection screening market. In addition, our Molecular Solutions business provides microbiome laboratory services that accelerate research and discovery for customers in the pharmaceutical, agricultural, and academic research markets. Financial results of Diversigen and Novosanis are included in our Molecular Solutions segment. We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated. The following table summarizes operating segment information for the three months ended March 31, 2021 and 2020, and asset information as of March 31, 2021 and December 31, 2020: Three Months Ended March 31, 2021 2020 Net revenues: Diagnostics $ 14,546 $ 17,792 Molecular Solutions 44,036 13,804 Total $ 58,582 $ 31,596 Operating income (loss): Diagnostics $ (12,193 ) $ (7,641 ) Molecular Solutions 22,615 (405 ) Total $ 10,422 $ (8,046 ) Depreciation and amortization: Diagnostics $ 890 $ 861 Molecular Solutions 1,599 1,336 Total $ 2,489 $ 2,197 Capital expenditures: Diagnostics $ 7,637 $ 818 Molecular Solutions 3,424 1,777 Total $ 11,061 $ 2,595 March 31, 2021 December 31, 2020 Total assets: Diagnostics $ 221,858 $ 242,613 Molecular Solutions 234,638 211,859 Total $ 456,496 $ 454,472

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying interim unaudited consolidated financial statements include the accounts of OraSure and its wholly-owned subsidiaries, DNAG, Diversigen and Novosanis. All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated. The unaudited financial statements, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. Results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results of operations expected for the full year. Summary of Significant Accounting Policies There have been no changes to the Company's significant accounting policies described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 that have had a material impact on the consolidated financial statements and related notes except as discussed herein.
Investments	Investments We consider all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss. We record an allowance for credit loss for our available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. As of March 31, 2021, we determined that the decline in the market value of our available-for-sale investment was not due to credit-related factors and as such no allowance for credit-loss was necessary. The following is a summary of our available-for-sale securities as of March 31, 2021 and December 31, 2020: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value March 31, 2021 Guaranteed investment certificates $ 25,470 $ — $ — $ 25,470 Corporate bonds 37,643 48 (375 ) 37,316 Total available-for-sale securities $ 63,113 $ 48 $ (375 ) $ 62,786 December 31, 2020 Guaranteed investment certificates $ 25,132 $ — $ — $ 25,132 Corporate bonds 71,533 135 (483 ) 71,185 Total available-for-sale securities $ 96,665 $ 135 $ (483 ) $ 96,317 At March 31, 2021, maturities of our available-for-sale securities were as follows: Less than one year $ 29,334 $ 48 $ (302 ) $ 29,080 Greater than one year $ 33,779 $ — $ (73 ) $ 33,706
Fair Value of Financial Instruments	Fair Value of Financial Instruments As of March 31, 2021 and December 31, 2020, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature. Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). All of our available-for-sale debt securities are measured as Level 2 instruments as of March 31, 2021 and December 31, 2020. Our guaranteed investment certificates are measured as Level 1 instruments as of March 31, 2021 and December 31, 2020. Included in cash and cash equivalents at March 31, 2021 and December 31, 2020, was We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant assets
Accounts Receivable	Accounts Receivable. Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.
Inventories	Inventories. Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating, which can be extended in certain circumstances. We continually evaluate quantities on hand and the carrying value of our inventories to determine the need for reserves for excess and obsolete inventories, based on prior experience as well as estimated forecasts of product sales. We reserve for unidentified scrap or spoilage based on historical write-off rates. We also consider items identified through specific identification procedures in assessing the adequacy of our reserve. When factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off, as in the case of lapsing expiration dates.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations. Accumulated depreciation of property, plant and equipment as of March 31, 2021 and December 31, 2020 was $55,251 and $53,604, respectively.
Intangible Assets	Intangible Assets . Intangible assets consist of customer relationships, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years. Accumulated amortization of intangible assets as of March 31, 2021 and December 31, 2020 was $28,128 and $27,107, respectively. The decrease in intangibles from $17,904 as of December 31, 2020 to $16,945 as of March 31, 2021 is due to $812 in amortization expense and foreign currency translation losses of $147.
Goodwill	Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current generally accepted accounting principles (“GAAP”) permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit . The increase in goodwill from $40,351 as of December 31, 2020 to $40,493 as of March 31, 2021 i s a result of an
Foreign Currency Translation	Foreign Currency Translation . The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than a functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income in our consolidated statements of income were $(576) and $693 for the three months ended March 31, 2021 and 2020, respectively.
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets. We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations for those subsidiaries are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at March 31, 2021 consists of $7,397 of currency translation adjustments and $327 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investment portfolio. Accumulated other comprehensive loss at December 31, 2020 consists of $8,749 of currency translation adjustments and $348 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investments portfolio.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The purpose of this update is to provide optional guidance for a limited time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this update are elective and are effective upon issuance for all entities. Management is evaluating the impact of this ASU and does not expect this update to have a material impact on the Company's Consolidated Financial Statements .
Revenues by Product	Revenues by product . The following table represents total net revenues by product line: Three Months Ended March 31, 2021 2020 Infectious disease testing $ 11,371 $ 14,664 Risk assessment testing 1,962 3,000 Genomics 11,064 8,393 Microbiome 2,088 1,577 COVID-19 27,389 394 Laboratory services 2,497 2,415 Other product and service revenues 208 443 Net product and services revenues 56,579 30,886 Royalty income 1,261 446 Other non-product revenues 742 264 Other revenues 2,003 710 Net revenues $ 58,582 $ 31,596
Revenues by Geographic Area	Revenues by geographic area . The following table represents total net revenues by geographic area, based on the location of the customer: Three Months Ended March 31, 2021 2020 United States $ 49,100 $ 21,616 Europe 4,552 2,805 Other regions 4,930 7,175 $ 58,582 $ 31,596
Customer and Vendor Concentrations	Customer and Vendor Concentrations . We had no significant customer concentrations (greater than 10%) in our accounts receivable at March 31, 2021. One of our customers accounted for 11% of our accounts receivable as of December 31, 2020. One customer accounted for 17% of net consolidated revenues for the three months ended March 31, 2021. We had no significant customer concentrations in our net consolidated revenues for the three months ended March 31, 2020. We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Third-party suppliers also manufacture certain products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations .
Deferred Revenue	Deferred Revenue . We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of March 31, 2021 and December 31, 2020 includes customer prepayments of $3,000 and $3,216, respectively. Deferred revenue as of March 31, 2021 and December 31, 2020 also includes $1,580 and $1,595, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that average price.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Available-for-sale Securities	The following is a summary of our available-for-sale securities as of March 31, 2021 and December 31, 2020: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value March 31, 2021 Guaranteed investment certificates $ 25,470 $ — $ — $ 25,470 Corporate bonds 37,643 48 (375 ) 37,316 Total available-for-sale securities $ 63,113 $ 48 $ (375 ) $ 62,786 December 31, 2020 Guaranteed investment certificates $ 25,132 $ — $ — $ 25,132 Corporate bonds 71,533 135 (483 ) 71,185 Total available-for-sale securities $ 96,665 $ 135 $ (483 ) $ 96,317 At March 31, 2021, maturities of our available-for-sale securities were as follows: Less than one year $ 29,334 $ 48 $ (302 ) $ 29,080 Greater than one year $ 33,779 $ — $ (73 ) $ 33,706

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2021
Business Combinations [Abstract]
Summary of Change in Contingent Consideration	The following table represents the change in contingent consideration: Balance as of December 31, 2020 $ 2,451 Payments made during the period (406 ) Change in fair value during the period (806 ) Balance as of March 31, 2021 $ 1,239

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventories	March 31, 2021 December 31, 2020 Raw materials $ 15,484 $ 15,425 Work in process 3,857 2,572 Finished goods 21,009 13,866 $ 40,350 $ 31,863

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Computations of Basic and Diluted Earnings (Loss) Per Share	The computations of basic and diluted earnings (loss) per share are as follows: Three Months Ended March 31, 2021 2020 Net income (loss) $ 3,774 $ (7,328 ) Weighted-average shares of common stock outstanding: Basic 71,878 61,927 Dilutive effect of stock options, restricted stock, and performance stock units 888 — Diluted 72,766 61,927 Earnings (loss) per share: Basic $ 0.05 $ (0.12 ) Diluted $ 0.05 $ (0.12 )

Revenues (Tables)

Revenues (Tables)	3 Months Ended
	Mar. 31, 2021
Revenue From Contract With Customer [Abstract]
Disaggregation of Revenue by Product and Geographic Area	Revenues by product . The following table represents total net revenues by product line: Three Months Ended March 31, 2021 2020 Infectious disease testing $ 11,371 $ 14,664 Risk assessment testing 1,962 3,000 Genomics 11,064 8,393 Microbiome 2,088 1,577 COVID-19 27,389 394 Laboratory services 2,497 2,415 Other product and service revenues 208 443 Net product and services revenues 56,579 30,886 Royalty income 1,261 446 Other non-product revenues 742 264 Other revenues 2,003 710 Net revenues $ 58,582 $ 31,596 Revenues by geographic area . The following table represents total net revenues by geographic area, based on the location of the customer: Three Months Ended March 31, 2021 2020 United States $ 49,100 $ 21,616 Europe 4,552 2,805 Other regions 4,930 7,175 $ 58,582 $ 31,596

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2021
Payables And Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	March 31, 2021 December 31, 2020 Payroll and related benefits $ 8,037 $ 14,769 Professional fees 1,150 978 Accrued income taxes 2,507 — Sales tax payable 2,572 2,400 Other 2,737 4,080 $ 17,003 $ 22,227

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Lessee Disclosure [Abstract]
Summary of Components of Lease Expense	The components of lease expense are as follows: Three Months Ended 2021 2020 Operating Lease Cost $ 420 $ 313 Finance Lease Cost Amortization of right-of use assets 127 163 Interest on lease liabilities 14 20 Total Finance Lease Cost $ 141 $ 183
Summary of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases is as follows: Three Months Ended 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 408 $ 316 Operating cash flows from financing leases 14 20 Financing cash flows from financing leases 282 175 Non-cash activity: Right-of-use assets obtained in exchange for operating lease obligations 629 — Right-of-use assets obtained in exchange for finance lease obligations — —
Summary of Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases is as follows: March 31, 2021 December 31, 2020 Operating Leases Right-of-use assets $ 4,871 $ 4,461 Current lease liabilities 1,443 1,125 Non-current lease liabilities 3,557 3,591 Total operating lease liabilities $ 5,000 $ 4,716 Finance Leases Right-of-use assets $ 1,184 $ 1,312 Current lease liabilities 522 517 Non-current lease liabilities 762 895 Total finance lease liabilities $ 1,284 $ 1,412
Summary of Lease Term and Discount Rate	Weighted Average Remaining Lease Term Weighted-average remaining lease term—operating leases 3.99 Weighted-average remaining lease term—finance leases 2.43 Weighted Average Discount Rate Weighted-average discount rate—operating leases 4.12 % Weighted-average discount rate—finance leases 4.39 %
Schedule of Minimum Lease Payments by Period Expected	As of March 31, 2021, minimum lease payments by period are expected to be as follows: Finance Operating 2021 (excluding the three months ended March 31, 2021) $ 424 $ 1,236 2022 566 1,616 2023 336 901 2024 25 909 2025 5 518 Thereafter — 323 Total Minimum Lease Payments 1,356 5,503 Less: imputed interest (72 ) (503 ) Present Value of Lease Liabilities $ 1,284 $ 5,000

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Summary of Reconciliation of Changes in Stockholders' Equity	Reconciliation of the changes in stockholders' equity for the three months ended March 31, 2021 and 2020 Common Stock Additional Paid-in Accumulated Other Comprehensive Accumulated Shares Amount Capital Loss Deficit Total Balance at December 31, 2020 71,738 $ — $ 505,123 $ (9,097 ) $ (97,455 ) $ 398,571 Common stock issued upon exercise of options 11 — 92 — — 92 Vesting of restricted stock and performance stock units 318 — — — — Purchase and retirement of common shares (111 ) — (1,730 ) — — (1,730 ) Stock-based compensation — — 1,464 — — 1,464 Net income — — — — 3,774 3,774 Currency translation adjustments — — — 1,352 — 1,352 Unrealized gain on marketable securities — — — 21 — 21 Balance at March 31, 2021 71,956 $ — $ 504,949 $ (7,724 ) $ (93,681 ) $ 403,544 Common Stock Additional Paid-in Accumulated Other Comprehensive Accumulated Shares Amount Capital Loss Deficit Total Balance at December 31, 2019 61,731 $ — $ 401,814 $ (12,136 ) $ (82,533 ) $ 307,145 Common stock issued upon exercise of options 6 — 30 — — 30 Vesting of restricted stock and performance stock units 486 — — — — — Purchase and retirement of common shares (197 ) — (1,408 ) — — (1,408 ) Stock-based compensation — — 1,376 — — 1,376 Net loss — — — — (7,328 ) (7,328 ) Currency translation adjustments — — — (9,221 ) — (9,221 ) Unrealized loss on marketable securities — — — (442 ) — (442 ) Balance at March 31, 2020 62,026 $ — $ 401,812 $ (21,799 ) $ (89,861 ) $ 290,152
Summary of Company's Stock Option Activity	The following table summarizes the stock option activity for the three months ended March 31, 2021: Options Outstanding on January 1, 2021 1,232 Granted 252 Exercised (11 ) Forfeited (23 ) Outstanding on March 31, 2021 1,450
Summary of Time-Vested Restricted Stock Award and Restricted Stock Units Activity	The following table summarizes time-vested restricted stock award and restricted stock unit activity for the three months ended March 31, 2021: Units Issued and unvested, January 1, 2021 659 Granted 275 Vested (206 ) Forfeited (5 ) Issued and unvested, March 31, 2021 723
Performance Based Restricted Stock Unit [Member]
Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan	The following table summarizes the PSU activity for the three months ended March 31, 2021: Units Issued and unvested, January 1, 2021 651 Granted 186 Performance adjustment 37 Vested (112 ) Forfeited (49 ) Issued and unvested, March 31, 2021 713

Business Segment Information (T

Business Segment Information (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Summary of Operating Segment and Asset Information	The following table summarizes operating segment information for the three months ended March 31, 2021 and 2020, and asset information as of March 31, 2021 and December 31, 2020: Three Months Ended March 31, 2021 2020 Net revenues: Diagnostics $ 14,546 $ 17,792 Molecular Solutions 44,036 13,804 Total $ 58,582 $ 31,596 Operating income (loss): Diagnostics $ (12,193 ) $ (7,641 ) Molecular Solutions 22,615 (405 ) Total $ 10,422 $ (8,046 ) Depreciation and amortization: Diagnostics $ 890 $ 861 Molecular Solutions 1,599 1,336 Total $ 2,489 $ 2,197 Capital expenditures: Diagnostics $ 7,637 $ 818 Molecular Solutions 3,424 1,777 Total $ 11,061 $ 2,595 March 31, 2021 December 31, 2020 Total assets: Diagnostics $ 221,858 $ 242,613 Molecular Solutions 234,638 211,859 Total $ 456,496 $ 454,472

The Company - Additional Inform

The Company - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2021Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of Segments of company	2

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 63,113	$ 96,665
Gross Unrealized Gains	48	135
Gross Unrealized Losses	(375)	(483)
Fair Value	62,786	96,317
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	25,470	25,132
Gross Unrealized Gains	0	0
Fair Value	25,470	25,132
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	37,643	71,533
Gross Unrealized Gains	48	135
Gross Unrealized Losses	(375)	(483)
Fair Value	37,316	$ 71,185
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	29,334
Gross Unrealized Gains	48
Gross Unrealized Losses	(302)
Fair Value	29,080
Greater Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	33,779
Gross Unrealized Gains	0
Gross Unrealized Losses	(73)
Fair Value	$ 33,706

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 177,676		$ 160,802
Fair value of plan assets	2,396		2,565
Accumulated depreciation of property and equipment	55,251		53,604
Accumulated amortization of intangible assets	28,128		27,107
Intangible Assets, Net	16,945		17,904
Intangible Assets, Accumulated Amortization	812
Intangible Assets, Foreign currency translation losses	147
Amount of goodwill at period end	40,493		40,351
Goodwill, acquired during period	18
Adjustment in goodwill associated with foreign currency translation	124
Net foreign exchange gains (losses)	(576)	$ 693
Accumulated foreign currency adjustments included in other comprehensive loss amounted	7,397		8,749
Unrealized loss on marketable securities	$ 327		348
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	5 years
Minimum [Member] | Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	20 years
Minimum [Member] | Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] | Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] | Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	15 years
Maximum [Member] | Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	40 years
Maximum [Member] | Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] | Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] | Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Money Market Fund [Member] | Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 72,979		$ 71,489

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands	Jul. 22, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Business Acquisition [Line Items]
Business acquisition contingent consideration, non-current		$ 874		$ 2,049
UrSure Inc [Member]
Business Acquisition [Line Items]
Purchase price	$ 3,000
Acquisition-related costs		$ 0	$ 393
Business acquisition contingent consideration, non-current	$ 28,000
Business combination contingent consideration expected payment period	4 years
Estimated fair value of contingent consideration	$ 3,440

Business Combinations - Summary

Business Combinations - Summary of Change in Contingent Consideration (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Business Combination Contingent Consideration Arrangements [Abstract]
Beginning Balance	$ 2,451
Payments made during the period	(406)
Change in fair value during the period	(806)	$ 1,110
Ending Balance	$ 1,239

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory Net [Abstract]
Raw materials	$ 15,484	$ 15,425
Work in process	3,857	2,572
Finished goods	21,009	13,866
Inventories	$ 40,350	$ 31,863

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory Net [Abstract]
Inventories	$ 40,350	$ 31,863
Pre-launch inventory associated with COVID products	$ 2,722

Earnings (Loss) Per Share - Com

Earnings (Loss) Per Share - Computations of Basic and Diluted Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
NET INCOME (LOSS)	$ 3,774	$ (7,328)
SHARES USED IN COMPUTING INCOME (LOSS) PER SHARE:
BASIC	71,878	61,927
Dilutive effect of stock options, restricted stock, and performance stock units	888
Diluted	72,766	61,927
BASIC	$ 0.05	$ (0.12)
DILUTED	$ 0.05	$ (0.12)

Earnings (Loss) Per Share - Add

Earnings (Loss) Per Share - Additional Information (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Common Stock Options Unvested Restricted Stock and Unvested Performance Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Number of anti-dilutive securities excluded from EPS computation	421	312

Revenues - Summary of Total Net

Revenues - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Net revenues	$ 58,582	$ 31,596
Product and Services Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	56,579	30,886
Product and Services Revenues [Member] | Infectious Disease Testing [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	11,371	14,664
Product and Services Revenues [Member] | Risk Assessment Testing [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	1,962	3,000
Product and Services Revenues [Member] | Genomics [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	11,064	8,393
Product and Services Revenues [Member] | Microbiome [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,088	1,577
Product and Services Revenues [Member] | COVID-19 [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	27,389	394
Product and Services Revenues [Member] | Laboratory Services [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,497	2,415
Product and Services Revenues [Member] | Other Product and Service Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	208	443
Other [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,003	710
Other [Member] | Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	1,261	446
Other [Member] | Other Non Product Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 742	$ 264

Revenues - Summary of Total N_2

Revenues - Summary of Total Net Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Net revenues	$ 58,582	$ 31,596
United States [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	49,100	21,616
Europe [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	4,552	2,805
Other Regions [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 4,930	$ 7,175

Revenues - Additional Informati

Revenues - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Revenue from contract with customer [Line Items]
Deferred revenue	$ 4,580	$ 4,811
Long-term Contract [Member]
Revenue from contract with customer [Line Items]
Deferred revenue	1,580	1,595
Up Front Payment Arrangement [Member]
Revenue from contract with customer [Line Items]
Deferred revenue	$ 3,000	$ 3,216
Customer [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk		11.00%
Customer [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | Maximum [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk	10.00%
Customer [Member] | Net Consolidated Revenue [Member] | Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk	17.00%

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Accrued Liabilities Current [Abstract]
Payroll and related benefits	$ 8,037	$ 14,769
Professional fees	1,150	978
Accrued income taxes	2,507
Sales tax payable	2,572	2,400
Other	2,737	4,080
Accrued expenses and other current liabilities, Total	$ 17,003	$ 22,227

Leases - Additional Information

Leases - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2021
Lessee Lease Description [Line Items]
Lessee operating and financing lease existence of option to terminate	true
Lessee operating and financing leases, period of options to terminate	1 year
Lessee, operating and finance lease, existence of option to extend	true
Minimum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	7 years

Leases - Summary of Components

Leases - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Lease Cost [Abstract]
Operating Lease Cost	$ 420	$ 313
Finance Lease Cost
Amortization of right-of use assets	127	163
Interest on lease liabilities	14	20
Total Finance Lease Cost	$ 141	$ 183

Leases - Summary of Supplementa

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 408	$ 316
Operating cash flows from financing leases	14	20
Financing cash flows from financing leases	282	$ 175
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations	$ 629

Leases - Summary of Supplemen_2

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Operating Leases
Right-of-use assets	$ 4,871	$ 4,461
Current lease liabilities	1,443	1,125
Non-current lease liabilities	3,557	3,591
Total operating lease liabilities	5,000	4,716
Finance Leases
Right-of-use assets	1,184	1,312
Current lease liabilities	522	517
Non-current lease liabilities	762	895
Total finance lease liabilities	$ 1,284	$ 1,412

Leases - Summary of Lease Term

Leases - Summary of Lease Term and Discount Rate (Detail)	Mar. 31, 2021
Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	3 years 11 months 26 days
Weighted-average remaining lease term—finance leases	2 years 5 months 4 days
Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.12%
Weighted-average discount rate—finance leases	4.39%

Leases - Schedule of Minimum Le

Leases - Schedule of Minimum Lease Payments by Period Expected (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Finance Lease Liabilities, Payments, Due [Abstract]
2021 (excluding the three months ended March 31, 2021)	$ 424
2022	566
2023	336
2024	25
2025	5
Total Minimum Finance Lease Payments	1,356
Less: imputed interest	(72)
Present Value of Finance Lease Liabilities	1,284	$ 1,412
Operating Lease Liabilities, Payments Due [Abstract]
2021 (excluding the three months ended March 31, 2021)	1,236
2022	1,616
2023	901
2024	909
2025	518
Thereafter	323
Total Minimum Operating Lease Payments	5,503
Less: imputed interest	(503)
Present Value of Operating Lease Liabilities	$ 5,000	$ 4,716

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Reconciliation of Changes in Stockholders' Equity (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Beginning Balance	$ 398,571	$ 307,145
Common stock issued upon exercise of options	$ 92	30
Common stock issued upon exercise of options, Shares	11
Purchase and retirement of common shares	$ (1,730)	(1,408)
Stock-based compensation	1,464	1,376
Net income (loss)	3,774	(7,328)
Currency translation adjustments	1,352	(9,221)
Unrealized gain (loss) on marketable securities	21	(442)
Ending Balance	$ 403,544	$ 290,152
Common Stock [Member]
Beginning Balance, Shares	71,738	61,731
Common stock issued upon exercise of options, Shares	11	6
Vesting of restricted stock and performance stock units, Shares	318	486
Purchase and retirement of common shares, Shares	(111)	(197)
Ending Balance, Shares	71,956	62,026
Additional Paid-in Capital [Member]
Beginning Balance	$ 505,123	$ 401,814
Common stock issued upon exercise of options	92	30
Purchase and retirement of common shares	(1,730)	(1,408)
Stock-based compensation	1,464	1,376
Ending Balance	504,949	401,812
Accumulated Other Comprehensive Loss [Member]
Beginning Balance	(9,097)	(12,136)
Currency translation adjustments	1,352	(9,221)
Unrealized gain (loss) on marketable securities	21	(442)
Ending Balance	(7,724)	(21,799)
Accumulated Deficit [Member]
Beginning Balance	(97,455)	(82,533)
Net income (loss)	3,774	(7,328)
Ending Balance	$ (93,681)	$ (89,861)

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 1,464,000	$ 1,376,000
Proceeds from exercise of stock options	92,000	30,000
Income tax benefit realized from stock option exercises during period	0	0
Amount share repurchase program of common shares			$ 25,000,000
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	250,000	253,000
Proceeds from exercise of stock options	92,000	30,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 1,036,000	1,079,000
Performance Based Restricted Stock [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Performance Based Restricted Stock [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 178,000	$ 44,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	0	0

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2021shares
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward
Options, Outstanding, Beginning Balance	1,232
Options, Granted	252
Options, Exercised	(11)
Options, Forfeited	(23)
Options, Outstanding, Ending Balance	1,450

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Time-Vested Restricted Stock Award and Restricted Stock Units Activity (Detail) - Restricted Stock Award and Restricted Stock Units [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	659
Shares, Granted	275
Shares, Vested	(206)
Shares, Forfeited	(5)
Shares, Issued and unvested, Ending Balance	723

Stockholders' Equity - Summar_4

Stockholders' Equity - Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan (Detail) - Performance Based Restricted Stock Unit [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	651
Shares, Granted	186
Performance adjustment	37
Shares, Vested	(112)
Shares, Forfeited	(49)
Shares, Issued and unvested, Ending Balance	713

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 6,529	$ 712

Business Segment Information -

Business Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2021Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business Segment Information _2

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Segment Reporting Information [Line Items]
Net revenues	$ 58,582	$ 31,596
Operating income (loss)	10,422	(8,046)
Depreciation and amortization	2,489	2,197
Capital expenditures	11,061	2,595
Total assets	456,496		$ 454,472
Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenues	14,546	17,792
Operating income (loss)	(12,193)	(7,641)
Depreciation and amortization	890	861
Capital expenditures	7,637	818
Total assets	221,858		242,613
Molecular Solutions [Member]
Segment Reporting Information [Line Items]
Net revenues	44,036	13,804
Operating income (loss)	22,615	(405)
Depreciation and amortization	1,599	1,336
Capital expenditures	3,424	$ 1,777
Total assets	$ 234,638		$ 211,859